- |||||||||| NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: guardian (clinicaltrials.gov) - Sep 27, 2011 P3, N=150, Completed, No longer recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
New P3 trial: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Sep 12, 2011 P3, N=24, Terminated,
- |||||||||| gandotinib (LY 2784544) / Eli Lilly
Enrollment change: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Sep 6, 2011 P1, N=80, Active, not recruiting, Not yet recruiting --> Recruiting N=60 --> 80
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, IO biomarker: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Sep 1, 2011 P2, N=48, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Trial completion: Imaging in MGUS, SMM and MM (clinicaltrials.gov) - Aug 23, 2011
P2, N=31, Completed, Recruiting --> Completed Recruiting --> Completed
|